Abstract: A method for treating a patient with a vascular disease condition by improving blood flow is provided. The method may include providing the patient with a vascular disease condition; testing a level of EO in the patient; determining, based on the tested level and a threshold level, that EO up-regulation (or EO down-regulation) would facilitate increased Prostacyclin release; providing a medical composition; and administering the medical composition to the patient. The medical composition may include a first dosage of a GABA-a agonist, a second dosage of an Angiotensin II modulator, and a third dosage of at least one EO-regulating compound. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, the ARB being an Angiotensin II, type 1 receptor antagonist. The at least one EO-regulating compound may be effective to up-regulate (or down-regulate) EO in blood vessels affected by the vascular disease condition. A medical composition is also provided.

Abstract: A medical composition for treatment of a peripheral vascular disease is provided. The medical composition may include a dosage of a GABA-a agonist, a dosage of an Angiotensin II modulator, and a dosage of a Direct Oral Anticoagulant. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, the ARB being an Angiotensin II, type 1 receptor antagonist. A method for treating a patient with a microvascular disease condition is provided. The patient may be provided, the medical composition may be provided, and the medical composition may be administered. The step of providing the patient may include providing a patient with at least one of systemic sclerosis, vascular insufficiency, distal ischemia, COVID-19 infection, and sepsis.

Abstract: A method for treating irritable bowel disease or irritable bowel syndrome is provided. The method may include steps of providing a patient suffering from irritable bowel disease or irritable bowel syndrome; providing a dosage of an Angiotensin II modulator and a dosage of an GABA-a agonist; and co-administering the dosages. The method may further include a step of increasing prostacyclin release in blood vessels of the patient's mesenteric or splanchnic circuit through action of the Angiotensin II modulator and the GABA-a agonist. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, wherein the ARB is an Angiotensin II, type 1 receptor antagonist. A dosage of an AT2 agonist may also be provided and co-administered.

Abstract: A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analogue, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analogue into a deliverable form.

Abstract: A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analog, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analog into a deliverable form.

Abstract: A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analogue, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analogue into a deliverable form.